On August 19, 2026, in Woburn, Massachusetts, Replimune Group, Inc. revealed that the Company's Chief Commercial Officer, Michelle DiNapoli, was granted inducement equity awards. Replimune Group, Inc., listed on NASDAQ as REPL, is a biotechnology company in the commercial stage focusing on innovative oncolytic immunotherapies.